Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is benefiting from a growing market for respiratory care devices due to an aging population and increasing prevalence of obesity. The company's recent focus on digital health and data collection sets it apart from competitors. While some segments may have underperformed, cost-cutting efforts and strong margin performance have contributed to solid financial results and increasing guidance for the future.

Bears say

ResMed is facing potential risks with the utilization of its CPAP technology and potential competition from GLP-1 therapeutics, potentially impacting revenue and market share. Despite these risks, the company may continue to gain market share and have a stronger financial performance from recent acquisitions, leading to a higher valuation. However, with an outlook of increased competition and potential disruptions, there may be limited upside potential for the company's stock.

ResMed (RMD) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Buy based on their latest research and market trends.

According to 10 analysts, ResMed (RMD) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $292.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $292.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.